This study will be enrolling 10 patients, ages 2-18 years old, with a confirmed
genetic/clinical diagnosis of CDKL5 Deficiency Disorder (CDD) in an open label trial of
fenfluramine for seizure control. Patients will be titrated over 14 days to a dose of ZX008
0.8 mg/kg/day (maximum dose 30 mg/d).
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health